Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genzyme's tissue conglomerate

Genzyme's tissue conglomerate

It has proven to be more difficult to develop products for wound healing and tissue repair than companies initially anticipated. In two separate technology acquisitions this summer, Genzyme Corp. has put together a new business unit that it believes will have the most comprehensive technology base in tissue repair.

GENZ's approach to the problem starts from the assumption that others have approached the area piecemeal, when instead a multifaceted approach to each clinical problem is required.

For GENZ, the

Read the full 822 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers